Telix Pharmaceuticals has submitted a BLA to the U.S. FDA for TLX250-CDx (Zircaix™), a PET scan diagnostic agent for clear cell renal cell carcinoma.

Santhera Pharmaceuticals has declared that its drug, AGAMREE® (vamorolone), has received authorization within the European Union to be prescribed for those diagnosed with Duchenne muscular dystrophy.

InnoCare Pharma has announced that their phase II trial of the novel TYK2 inhibitor ICP-332 met its primary endpoint in treating adults with moderate to severe atopic dermatitis.

Caliway Finalizes Funding Round Exceeding Targets, Locks in Excess of $100M for Critical Phase 3 Trial of CBL-514 for Subcutaneous Fat Reduction.

Wave Life Sciences has commenced the Phase 2 FORWARD-53 study, beginning treatment with WVE-N531 for individuals with Duchenne Muscular Dystrophy.

LEO Pharma Inc. has disclosed that the FDA has recently broadened the sanctioned use of Adbry (tralokinumab-ldrm) by authorizing its application for young individuals.

FDA greenlights the unique combination of enfortumab vedotin (PADCEV®) and pembrolizumab (KEYTRUDA®), marking the first coalescence of an ADC and PD-1 inhibitor to combat progressive bladder carcinoma.

Cullinan Oncology has initiated a Phase 1 study of CLN-617, an innovative biologic that combines the properties of IL-2 and IL-12 cytokines

CSL, a major biotech player, announced that the FDA has accepted its application for the once-monthly hereditary angioedema preventative drug, garadacimab (CSL312).

Travere Therapeutics has begun a critical Phase 3 study of Pegtibatinase in the management of Classical Homocystinuria (HCU).

Rezolute has commenced a pivotal Phase 3 clinical trial for its investigative drug, RZ358, aimed at treating patients with Congenital Hyperinsulinism.

Mission Therapeutics reveals that the FDA has given the green light to start a Phase II study for their prime candidate, MTX652, targeting Acute Kidney Injury.